Lyra Therapeutics Inc. (LYRA): Price and Financial Metrics
GET POWR RATINGS... FREE!
LYRA Stock Price Chart Interactive Chart >
LYRA Price/Volume Stats
|Current price||$8.99||52-week high||$16.50|
|Prev. close||$8.79||52-week low||$5.83|
|Day high||$9.18||Avg. volume||113,776|
|50-day MA||$7.34||Dividend yield||N/A|
|200-day MA||$9.74||Market Cap||116.88M|
Lyra Therapeutics Inc. (LYRA) Company Bio
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer and is headquartered in Watertown, MA.
Most Popular Stories View All
LYRA Latest News Stream
|Loading, please wait...|
LYRA Latest Social Stream
View Full LYRA Social Stream
Latest LYRA News From Around the Web
Below are the latest news stories about Lyra Therapeutics Inc that investors may wish to consider to help them evaluate LYRA as an investment opportunity.
Good morning, investors!
Based in Watertown, Massachusetts, Lyra Therapeutics, Inc. (LYRA) is a clinical stage biotechnology company, which develops a proprietary technology platform. The platform provides a treatment alternative to patients seeking care for ear, nose and throat diseases for which conventional medical approaches are either a second treatment option or have already failed to produce needed results. Lyra’s therapies are based on a single administration of anti-inflammatory bioresorbable polymer implants that are applied directly on the inflamed mucosa. These implants act continually for a sustained period of several months. The research and development pipeline includes LYR-210 and LYR-220, two innovative therapeutic solutions for the treatment of chronic rhinosinusitis.
LYRA Price Returns